Literature DB >> 17024575

Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line.

Alan Pourpak1, Robert T Dorr, Ross O Meyers, Marianne B Powell, Steven P Stratton.   

Abstract

Apomine, a novel bisphosphonate ester, has demonstrated anticancer activity in a variety of cancer cell lines; however, its mechanism of cytotoxicity is not well understood. Previous work has demonstrated that Apomine induces cell death by activation of caspase-3 in several cancer cell types. However, we have demonstrated that Apomine induces cell death in the A375 human melanoma cell line through a novel membrane-mediated mechanism that is independent of caspase-3 activation. This mechanism of membrane lysis may apply to other bisphosphonates and may be an important mechanism for overcoming resistance to apoptosis. Interestingly, Apomine-mediated cell death in the A375 and UACC 3093 human melanoma cell lines is also independent of N-Ras farnesylation, which was a previously described mechanism of action for Apomine in other cancer cell types. These data suggest that Apomine induces cell death through a novel plasma membrane-mediated cytolytic pathway, independent of caspase-3 activation and N-Ras farnesylation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17024575     DOI: 10.1007/s10637-006-9015-6

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  32 in total

1.  A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma.

Authors:  Karl D Lewis; John A Thompson; Jeffrey S Weber; William A Robinson; Steven O'Day; Jose Lutzky; Sewa S Legha; Simon Floret; Francis Ruvuna; Rene Gonzalez
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.850

2.  A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity.

Authors:  T Decker; M L Lohmann-Matthes
Journal:  J Immunol Methods       Date:  1988-11-25       Impact factor: 2.303

3.  Bile acid induces hydrophobicity-dependent membrane alterations.

Authors:  Sandeep Akare; Jesse D Martinez
Journal:  Biochim Biophys Acta       Date:  2005-06-15

4.  Induction of apoptosis in breast cancer cells by apomine is mediated by caspase and p38 mitogen activated protein kinase activation.

Authors:  Lorraine C Lowe; Siddhika G Senaratne; Kay W Colston
Journal:  Biochem Biophys Res Commun       Date:  2005-04-08       Impact factor: 3.575

5.  Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression.

Authors:  Katarina Omholt; Sofia Karsberg; Anton Platz; Lena Kanter; Ulrik Ringborg; Johan Hansson
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

Review 6.  Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.

Authors:  Matthijs R Graaf; Dick J Richel; Cornelis J F van Noorden; Henk-Jan Guchelaar
Journal:  Cancer Treat Rev       Date:  2004-11       Impact factor: 12.111

7.  Deoxycholic acid-induced apoptosis is switched to necrosis by bcl-2 and calphostin C.

Authors:  J M LaRue; E D Stratagoules; J D Martinez
Journal:  Cancer Lett       Date:  2000-04-28       Impact factor: 8.679

8.  The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.

Authors:  S C E Bolick; T H Landowski; D Boulware; M M Oshiro; J Ohkanda; A D Hamilton; S M Sebti; W S Dalton
Journal:  Leukemia       Date:  2003-02       Impact factor: 11.528

9.  Effects of adriamycin and hyperthermia on cellular uptake of [3H]thymidine and its significance for the incorporation into DNA.

Authors:  K Naito; Q He; S Skog; B Tribukait; L Andersson; H Hisazumi
Journal:  Int J Hyperthermia       Date:  1989 May-Jun       Impact factor: 3.914

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  3 in total

1.  Preformulation, formulation, and in vivo efficacy of topically applied apomine.

Authors:  Philip J Kuehl; Steven P Stratton; Marianne B Powell; Paul B Myrdal
Journal:  Int J Pharm       Date:  2009-08-20       Impact factor: 5.875

2.  Characterization of a membrane-active anti-tumor agent, UA8967.

Authors:  Robert T Dorr; Betty K Samulitis; Lee Wisner; Haiyong Han; Yu Zhao; Paul Beroza; Komath Damodaran; Suzu Igarashi; Terry H Landowski; Daniel D Von Hoff
Journal:  Invest New Drugs       Date:  2012-11-23       Impact factor: 3.850

3.  Outpatient Follow-up and Secondary Prevention for Melanoma Patients.

Authors:  Ryan G Gamble; Daniel Jensen; Andrea L Suarez; Anne H Hanson; Lauren McLaughlin; Jodi Duke; Robert P Dellavalle
Journal:  Cancers (Basel)       Date:  2010-06-07       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.